Japan Approves World's First Therapies Using Induced Pluripotent Stem Cells

Japan has made a historic breakthrough in medicine, becoming the first country in the world to approve commercial medicinal products based on induced pluripotent stem cells, commonly known as iPS cells. The marketing authorization decision was made by Japan's Ministry of Health, Labour and Welfare and was announced on March 6, 2026. The approval covers two therapies developed by the Tokyo-based biotechnology company Healios K.K.: "HLC-AMI-01" for the treatment of age-related macular degeneration (AMD) and "HLC-PDP-01" for Parkinson's disease. Induced pluripotent stem cells (iPS) are a breakthrough technology for which Shinya Yamanaka received the Nobel Prize in 2012. It involves reprogramming adult cells, e.g., skin cells, to an embryonic state from which virtually all types of body tissues can develop. This discovery was set to revolutionize regenerative medicine, promising treatment for incurable diseases without the ethical controversies associated with stem cells taken from embryos. The therapy for Parkinson's disease, which is the focus of most reports, involves implanting patients with dopamine progenitor cells grown from iPS cells from a healthy donor. These cells are intended to integrate into the brain and begin producing dopamine – a neurotransmitter whose deficiency is the direct cause of Parkinson's motor symptoms, such as tremors and stiffness. Unlike conventional drugs, which only alleviate symptoms, the cell therapy aims to rebuild damaged nerve tissue, offering a potentially permanent cure. A similar mechanism underlies the AMD therapy, where retinal pigment epithelial cells are implanted to halt progressive vision loss. „This is a historic step toward realizing iPS cell-based regenerative medicine.” — Shinya Yamanaka The company Healios, which developed the therapies, confirmed that after finalizing the price with Japanese authorities, it will begin their sale on the domestic market. Approval in Japan, known for its rigorous regulatory standards, also opens the door to seeking authorization in other key regions, including the United States and Europe. This success is the culmination of years of research and clinical trials that demonstrated both the safety and preliminary efficacy of these advanced therapies. The regulator's decision not only gives hope to millions of patients suffering from neurodegenerative and ophthalmological diseases but also sends a strong signal to the global biotechnology industry, confirming the real commercial potential of regenerative medicine. Japan, the birthplace of iPS technology, thereby strengthens its position as a world leader in this pioneering field of science.